Abstract
| Grant Number: | 1R43HL089987-01 |
| Project Title: | LUNGASOL/LUNGRECOV ? A Novel Lung Preservation Solution Platform |
Abstract:
DESCRIPTION (provided by applicant): Cell Preservation Services Inc. (CPSI) is a biopreservation company that develops new approaches and solutions to the hypothermic storage (4o to 8oC) and cryopreservation (- 196oC) of human cells, tissues and organs. CPSI works closely with BioLife Solutions Inc. that distributes the HypoThermosol (HTS) and CryoStor platforms of solutions to clients worldwide. HTS and CryoStor are serum-free and used in the stem cell and tissue engineering markets as well as by academic researchers for the improved long term storage of human cell strains and cell lines. One of the HTS variants, HTS-FRS, is used in applications that range from cellular cardiomyoplasty to hair follicle transplant. CPSI's approach is unique in the preservation sciences because the Company develops novel solutions based on the molecular investigation of the stress pathways activated by cells undergoing hypothermic storage and cryopreservation. Once defined, cell-matched solutions are developed that provide optimal protection during cold storage. CPSI intends to develop a unique set of linked solutions designed to improve lung preservation so that more lung transplant candidates are able to receive a donor lung. The Company will develop LUNGASOL and LUNGRECOV, both of which are intended to be used in a linked series. LUNGASOL will serve as the preservation solution whereas LUNGRECOV will be the recovery media used as the lung transits from 4 C o to 37 C. The latter is unique and especially important given that re-warming of lung tissue is o known to contribute to ischemia/reperfusion injury which is the major underlying cause of Primary Graft Dysfunction (PGD) of lung tissue. The two solutions will be developed by using a unique double-tiered assay of cDNA microarrays followed by shRNA that should first identify and then confirm the stress pathways that are activated in airway cells during hypothermic storage. Once identified, these pathways will be managed such that hypothermic preservation time and efficacy can be extended and optimized. Phase 2 will test both LUNGASOL and LUNGRECOV on whole, human lung tissue. Thus, the intent of this proposal is to develop prototype lung preservation solutions so that the donor lung tissue pool can be increased. The intent of this proposal is to develop a set of linked solutions for the improved preservation of lung tissue. This, in turn, should increase the number of lungs available for transplant.
Thesaurus Terms:
biomaterial development /preparation, biotechnology, cryopreservation, lung, lung transplantation, solution, tissue /organ preservation
apoptosis, cytotoxicity, hypothermia, injury prevention, reperfusion
cell line, complementary DNA, gene targeting, histology, human tissue, microarray technology
| Institution: | CELL PRESERVATION SERVICES, INC. |
| OWEGO, NY 13827 |
| Fiscal Year: | 2007 |
| Department: | |
| Project Start: | 15-SEP-2007 |
| Project End: | 31-AUG-2008 |
| ICD: | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE |
| IRG: | ZRG1 |
|
